The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss. Objective: Obesity affects more than 40 ...

Maintaining weight loss with regular exercise rather than the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, a drug used to treat ...

A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients who received glucagon-like peptide-1 receptor ...

Please provide your email address to receive an email when new articles are posted on . Results showed 14 days may be the optimal cutoff for glucagon-like peptide-1 receptor agonists prior to hip or ...

A large Cleveland Clinic study has found that people with obesity and type 2 diabetes who undergo weight-loss surgery live ...

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) - prescription ...

Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...

In a subgroup analysis, there was a positive effect in people with obesity, with significant reductions in brain reward center cue reactivity on functional magnetic resonance imaging. (HealthDay News) ...

This cohort study found that glucagon-like peptide-1 receptor agonist (GLP-1RA) prescriptions were associated with a lower risk of uveitis compared with controls. These findings suggest potential anti ...